Global Uveitis Pipeline Review, H2 2018 - 32 Companies & Drug Pipelines - ResearchAndMarkets.com

September 24, 2018

DUBLIN--(BUSINESS WIRE)--Sep 24, 2018--The “Uveitis - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Uveitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 3, 8, 6, 1, 25 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Uveitis - Overview Uveitis - Therapeutics Development Uveitis - Therapeutics Assessment Uveitis - Companies Involved in Therapeutics Development Uveitis - Drug Profiles Uveitis - Dormant Projects Uveitis - Discontinued Products Uveitis - Product Development Milestones Appendix Companies FeaturedAciont IncAldeyra Therapeutics IncAlvotech IcelandApitope International NVBristol-Myers Squibb CoClearside BioMedical IncCoherus BioSciences IncElasmogen LtdEnzo Biochem IncEyeGate Pharmaceuticals IncEyePoint Pharmaceuticals IncEyevensys SASF. Hoffmann-La Roche LtdFresenius SE & Co KGaAGalapagos NVHanAll Biopharma Co LtdIdera Pharmaceuticals IncJohnson & JohnsonKv1.3 TherapeuticsMidatech Pharma PlcMitotech SANemus Bioscience IncNovartis AGOncoNOx ApSOphthotech CorpOrchid Pharma LtdPalatin Technologies IncPanoptes Pharma GesmbHRe-Pharm LtdSandoz International GmbHSanten Pharmaceutical Co LtdSun Pharma Advanced Research Company LtdFor more information about this drug pipelines report visit https://www.researchandmarkets.com/research/458dn5/global_uveitis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005341/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Optical Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/24/2018 04:18 AM/DISC: 09/24/2018 04:18 AM


Update hourly